Refine
Has Fulltext
- yes (3)
Is part of the Bibliography
- yes (3)
Document Type
- Journal article (2)
- Doctoral Thesis (1)
Keywords
- CVID (1)
- European Society for Immunodeficiencies (ESID) (1)
- German PID-NET registry (1)
- IgG substitution therapy (1)
- PID prevalence (1)
- SV2C ADHD (1)
- SV2C ADHS (1)
- canonicalization (1)
- chemical identifier (1)
- cheminformatics (1)
In der Pathophysiologie von ADHS ist der Prozess der Neurotransmission bedeutsam für das Verständnis der Erkrankung. Gene wie SV2C, die synaptische Proteine kodieren, spielen eine wichtige Rolle bei der Signalübertragung und könnten daher für den Pathomechanismus von ADHS interessant sein. SV2C qualifiziert sich als Kandidatengen, da ihm eine regulatorische Aufgabe bei der Ausschüttung von Neurotransmittern zugeschrieben wird. Einen weiteren Hinweis auf die potentielle Beteiligung von SV2C an der Entstehung von ADHS ergab eine Studie des Labors für klinische Psychobiologie der Universität Würzburg. Dabei wurde mittels aCGH im Bereich von SV2C eine Duplikation entdeckt, welche auf eine Dysfunktion von SV2C bedingen könnte. In dieser Dissertation wurde SV2C in einer Stichprobe von 100 ADHS-Familien anhand von drei Tag-SNP des putativen Promotorbereichs analysiert. Mittels molekulargenetischer Methoden (PCR, Restriktionsverdau) wurden die Genotypen des Patientenkollektivs bezüglich dieser SNP bestimmt. Für keinen der drei untersuchten SNP konnte in dieser Arbeit eine signifikante Assoziation zu ADHS beschrieben werden. Weitere Studien hinsichtlich SV2C sind nötig, um die Funktion von SV2C im Kontext von ADHS herauszufinden.
TUCAN is a canonical serialization format that is independent of domain-specific concepts of structure and bonding. The atomic number is the only chemical feature that is used to derive the TUCAN format. Other than that, the format is solely based on the molecular topology. Validation is reported on a manually curated test set of molecules as well as a library of non-chemical graphs. The serialization procedure generates a canonical “tuple-style” output which is bidirectional, allowing the TUCAN string to serve as both identifier and descriptor. Use of the Python NetworkX graph library facilitated a compact and easily extensible implementation.
Introduction: The German PID-NET registry was founded in 2009, serving as the first national registry of patients with primary immunodeficiencies (PID) in Germany. It is part of the European Society for Immunodeficiencies (ESID) registry. The primary purpose of the registry is to gather data on the epidemiology, diagnostic delay, diagnosis, and treatment of PIDs.
Methods: Clinical and laboratory data was collected from 2,453 patients from 36 German PID centres in an online registry. Data was analysed with the software Stata® and Excel.
Results: The minimum prevalence of PID in Germany is 2.72 per 100,000 inhabitants. Among patients aged 1-25, there was a clear predominance of males. The median age of living patients ranged between 7 and 40 years, depending on the respective PID. Predominantly antibody disorders were the most prevalent group with 57% of all 2,453 PID patients (including 728 CVID patients). A gene defect was identified in 36% of patients. Familial cases were observed in 21% of patients. The age of onset for presenting symptoms ranged from birth to late adulthood (range 0-88 years). Presenting symptoms comprised infections (74%) and immune dysregulation (22%). Ninety-three patients were diagnosed without prior clinical symptoms. Regarding the general and clinical diagnostic delay, no PID had undergone a slight decrease within the last decade. However, both, SCID and hyper IgE-syndrome showed a substantial improvement in shortening the time between onset of symptoms and genetic diagnosis. Regarding treatment, 49% of all patients received immunoglobulin G (IgG) substitution (70%-subcutaneous; 29%-intravenous; 1%-unknown). Three-hundred patients underwent at least one hematopoietic stem cell transplantation (HSCT). Five patients had gene therapy.
Conclusion: The German PID-NET registry is a precious tool for physicians, researchers, the pharmaceutical industry, politicians, and ultimately the patients, for whom the outcomes will eventually lead to a more timely diagnosis and better treatment.